Tweets
#ACR21 @RheumNow
Abst#0370 by Afinogenova et al.
138 PCP surveyed on Chronic back pain evaluation
▶️58% rarely assess for IBP
▶️40% not comfortable diagnosing AS
▶️70% not comfortable diagnosing axSpA
Contributing to a lack of referral to rheumatology and delay in diagnosis.
swethaann23 @swethaann23 ( View Tweet )
4 years 9 months ago
Annual age-standardized mortality rate (ASMR) improved from 1999-2015, then worsened 2015-2019:
#ACR21 Abst#0454 @RheumNow https://t.co/mu1xIO7YlI
Pedro Castillo @_Castillo_Pedro ( View Tweet )
4 years 9 months ago
Race/ethnicity and residence were independent risk factors for LN mortality which was higher in:
➡️Black patients
➡️Those living in central metro areas
#ACR21 Abst#0454 @RheumNow
Pedro Castillo @_Castillo_Pedro ( View Tweet )
4 years 9 months ago
Prevention study using Abatacept in 100 patients with arthralgia is superior (61%) to placebo (31%) in improving subclinical inflammation in RA at-risk patients (ACPA+, MRI+, Arthralgia+) at 6 months. No new safety issue emerged @RheumNow #ACR21 Abst#0455 https://t.co/DoRItcHfBE
Dr. Antoni Chan @synovialjoints ( View Tweet )
4 years 9 months ago
Abst0453 #ACR21 @RheumNow integrated phase 2/3 trial results of il23 inhibitor Risankizumab (RZB) in PsA: significant improvement ACR20 at Week 24 (RZB 55.5% vs PBO 31.3%, P < 0.001), secondary endpoint met at HAQ DI, PASI, fatigue score& enthesitis. no new safety signals https://t.co/ZAVgswoXCf
Olga Petryna @DrPetryna ( View Tweet )
4 years 9 months ago
#ACR21 Abst#0456. Fxnal connectivity, ⬆️ blood-brain barrier (BBB) leakage & cognitive impairment (CI) in SLE
⭐️SLE pts ⬆️♀️, older, caucasian, ⬇️ edu than controls
⭐️CI in longer disease, APS
▶️ SLE CI:⬇️Brain-wide connections, BBB permeability
https://t.co/fen9OYhWhC @Rheumnow https://t.co/DMQfWCqUhh
Links:
Eric Dein @ericdeinmd ( View Tweet )
4 years 9 months ago
RZB tx resulted in statistically greater improvements in signs/ symptoms of PsA vs PBO and was well tolerated w/ no new safety signals. Plenary Abs 0453 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/c9RJdWlmpO https://t.co/MDbdAhdnIy
Dr. Rachel Tate @uptoTate ( View Tweet )
4 years 9 months ago
Serum IL-22 levels elevated in axSpA pts in Israeli study. Possible independent biomarker for the differentiation of AxSpA from its non-inflammatory mimickers? Possible target for treatment? Further studies needed. Abs 0385 #ACR21 #RheumNow @RheumNow https://t.co/AUwZFJTlnq https://t.co/WSZ2WjW45W
Dr. Rachel Tate @uptoTate ( View Tweet )
4 years 9 months ago
Can we stop RA developing? Not previously.
Double-blind RCT:
- arthralgias+ACPA+MRI changes
- but no clinical synovitis
- abatacept for 6m
didn't progress to arthritis: 92% v 65%
improvement in MRI: 61% v 31%
+ benefit to 18m not shown
"provocative"!
#ACR21 ABST0455 @RheumNow https://t.co/TGxCBhk4r9
David Liew @drdavidliew ( View Tweet )
4 years 9 months ago
New treatments in #psoriaticarthritis Deucravacitinib TYK2 inhibitor selectively mediates cytokine signaling, specific inflammatory pathways (eg, IL-23, IL-12, and Type I interferons) concomitant with clinical symptom improvement @RheumNow #ACR21 Abst#0490 https://t.co/7JZGa5R4eC
Dr. Antoni Chan @synovialjoints ( View Tweet )
4 years 9 months ago
Functional MRI eval neuro-connectivity in 78 SLE pts
Cognitive impairment occurred in 48%; pts had:
👉longer disease duration
👉likely +LAC
👉abnormal fMRI
👉>blood brain barrier permeability
#ACR21 #Plenary Abstr# 0456 @rheumnow https://t.co/WI5CD73rvM
TheDaoIndex @KDAO2011 ( View Tweet )
4 years 9 months ago
How about lipoprotein a as a potential biomarker for poor renal outcomes in #lupus?
Results of this study by Dr @CaoilfhionnMD and her group show that ⬆Lp(a) is strongly associated w/ proteinuria, ⬇ eGFR and ⬆PGA.
Interesting🤓
@RheumNow #ACR21 abs0327 https://t.co/MLgJ1tPJMp
sheila @RHEUMarampa ( View Tweet )
4 years 9 months ago
